Isatuximab

Generic name: Isatuximab
Brand names: Sarclisa
Dosage form: intravenous solution (irfc 20 mg/mL)
Drug class: CD38 monoclonal antibodies

Usage of Isatuximab

Isatuximab is used treat multiple myeloma in adults. Isatuximab is usually given in combination with another cancer medicine (Carfilzomib or pomalidomide) and a steroid (dexamethasone).

Isatuximab is given after other cancer treatments did not work or have stopped working.

Isatuximab may also be used for purposes not listed in this medication guide.

Isatuximab side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver if you feel cold, itchy, nauseated, feel like you might pass out, or have a cough, headache, stuffy or runny nose, a tight feeling in your throat, pounding heartbeats, fluttering in your chest, or trouble breathing.

Isatuximab may cause serious side effects. Call your doctor at once if you have:

  • easy bruising, unusual bleeding, purple or red spots under your skin;
  • low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing;
  • low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or
  • symptoms of pneumonia--cough with mucus, chest pain, feeling short of breath.
  • Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

    Common side effects of isatuximab may include:

  • low blood cell counts;
  • pneumonia;
  • diarrhea; or
  • cold symptoms such as stuffy nose, sneezing, sore throat;
  • This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Before taking Isatuximab

    You should not be treated with isatuximab if you are allergic to it.

    You may need to have a negative pregnancy test before starting this treatment.

    Isatuximab may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using isatuximab and for at least 5 months after your last dose.

    If you use isatuximab while you are pregnant, make sure any doctor caring for your new baby knows that you used this medicine during pregnancy. Being exposed to isatuximab in the womb could affect your baby's vaccination schedule during the first few months of life.

    You should not use isatuximab together with pomalidomide if you are pregnant or planning to become pregnant. Pomalidomide can cause severe, life-threatening birth defects with just one dose.

    Both men and women using pomalidomide should use effective birth control to prevent pregnancy. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using isatuximab and pomalidomide.

    You should not breastfeed while using isatuximab.

    Using isatuximab may increase your risk of developing other cancers. Ask your doctor about this risk.

    Relate drugs

    How to use Isatuximab

    Usual Adult Dose for Multiple Myeloma:

    IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE:-Cycle 1: 10 mg/kg IV on Days 1, 8, 15, and 22 (weekly)-Cycle 2 and beyond: 10 mg/kg IV on Days 1 and 15 (every 2 weeks)-Each treatment cycle consists of a 28-day period. -Therapy is repeated until disease progression or unacceptable toxicity.Recommended Premedications (administer 15 to 60 minutes prior to the infusion):-Dexamethasone 40 mg orally or IV (or 20 mg orally or IV for patients 75 years or older).-Acetaminophen 650 mg to 1000 mg orally (or equivalent).-H2 antagonists.-Diphenhydramine 25 to 50 mg orally or IV (or equivalent). The IV route is preferred for at least the first 4 infusions.Use: In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor

    Usual Geriatric Dose for Multiple Myeloma:

    IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE:-Cycle 1: 10 mg/kg IV on Days 1, 8, 15, and 22 (weekly)-Cycle 2 and beyond: 10 mg/kg IV on Days 1 and 15 (every 2 weeks)-Each treatment cycle consists of a 28-day period. -Therapy is repeated until disease progression or unacceptable toxicity.Recommended Premedications (administer 15 to 60 minutes prior to the infusion):-Dexamethasone 40 mg orally or IV (or 20 mg orally or IV for patients 75 years or older).-Acetaminophen 650 mg to 1000 mg orally (or equivalent).-H2 antagonists.-Diphenhydramine 25 to 50 mg orally or IV (or equivalent). The IV route is preferred for at least the first 4 infusions.Use: In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor

    Warnings

    Before using isatuximab tell your doctor about all your medical conditions or allergies, all medicines you use, and if you are pregnant or breastfeeding.

    What other drugs will affect Isatuximab

    Other drugs may affect isatuximab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords